$7.00—Stale · unknown old
NASDAQ • Last print unknown ago
$7.00—Stale · unknown old
Taiwan Liposome Company, Ltd. (TLC) is a biotechnology firm focused on developing innovative lipid-based drug delivery systems and therapeutics. The company primarily operates in Taiwan and has a pipeline that includes products targeting cancer and infectious diseases, leveraging its proprietary technologies to enhance drug efficacy and reduce side effects.
TLC generates revenue primarily through licensing its proprietary drug delivery technologies to pharmaceutical companies. The company has a strong competitive advantage due to its unique lipid-based formulations that improve the pharmacokinetics of drugs, allowing for better therapeutic outcomes.
Progress in clinical trials for lead candidates, such as TLC-1001 for cancer treatment
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for new drug applications
Changes in market dynamics for lipid-based drug delivery systems
Regulatory changes affecting drug approval processes
Technological disruption from new drug delivery methods
Emergence of alternative drug delivery technologies from competitors
Potential for larger pharmaceutical companies to develop in-house capabilities
High debt-to-equity ratio (1.52) indicating potential liquidity issues
Negative operating cash flow impacting financial stability
low - The biotechnology sector is often insulated from economic cycles, as healthcare demand remains relatively stable regardless of economic conditions.
Moderate - Higher interest rates could increase the cost of capital for R&D financing, potentially impacting the company's ability to fund its pipeline.
minimal - TLC's operations are not heavily reliant on credit markets, but its elevated debt levels could pose risks if cash flow does not improve.
growth - Investors looking for high-risk, high-reward opportunities in biotechnology.
high - The stock has historically exhibited high volatility due to its dependence on clinical trial outcomes and regulatory approvals.